Introduction
Methods
Inclusion and exclusion criteria
Search strategy
Quality assessment
Data extraction
Statistical analysis
Results
Characteristics of included studies and quality assessment
Name | Arm | Original | Country | Mean age(year) | Patients (Numbers) | Stage | OS (rate) | |
---|---|---|---|---|---|---|---|---|
I-II | III-IV | |||||||
Ki Sung Ryu2004 | Control group | Primary | South Korea | 47.7 | 60 | 21 | 39 | 52.8%(5-year) |
Experimental group | 46.1 | 57 | 22 | 35 | 63.4%(5-year) | |||
J. GORI 2005 | Control group | Primary | Argentina | 57.0 | 19 | 0 | 19 | 42.1%(5-year) |
Experimental group | 55.5 | 29 | 0 | 29 | 55.2%(5-year) | |||
FranciscOC2009 | Control group | Recurrence | Bulgaria | 54 | 12 | 0 | 12 | 17% (5-year) |
Experimental group | 54 | 14 | 0 | 14 | 57% (5-year) | |||
JIN HWI KIM 2010 | Control group | Primary | South Korea | 49 | 24 | 5 | 19 | 25%(8-year) |
Experimental group | 48 | 19 | 7 | 12 | 84.21%(8-year) | |||
Rene Warschkow 2012 | Control Group | Primary or Recurrence | Switzerland | 65 | 90 | 56 | 35 | 38.3%(5-year) |
Experimental group | 58.9 | 21 | 17 | 4 | 72.5%(5-year) | |||
Anna Fagotti 2012 | Control Group | Recurrence | Italy | 55 | 37 | 5 | 32 | 37.8%(5-year) |
Experimental group | 51 | 30 | 4 | 26 | 76.7%(5-year) | |||
TAMAR SAFRA 2014 | Control Group | Recurrence | Israel | 54.3 | 84 | 7 | 76 | 45%(5-year) |
Experimental group | 54.3 | 27 | 2 | 25 | 79%(5-year) | |||
Jean-Franc ̧ois Le Brun 2014 | Control Group | Recurrence | France | NR | 19 | 1 | 18 | 19.4%(4-year) |
Experimental group | NR | 23 | 2 | 21 | 75.6%(4-year) | |||
Cascales-Campos, P. A2014 | Control Group | Primary | Spain | 57 | 35 | 0 | 35 | NR |
Experimental group | 57 | 52 | 0 | 52 | NR | |||
J. Spiliotis 2015 | Control Group | Recurrence | Greece | 58.1 | 60 | 0 | 60 | 18%(3-year) |
Experimental group | 58.3 | 60 | 0 | 60 | 75%(3-year) | |||
Glauco Baiocchi 2016 | Control Group | Recurrence | Brazil | 58.4 | 50 | 10 | 40 | 49.5%(5-year) |
Experimental group | 51.6 | 29 | 2 | 27 | 49.7%(5-year) | |||
Alberto A. Mendivil 2017 | Control Group | Primary | USA | 62.9 | 69 | 0 | 69 | 75.3%(3-year) |
Experimental group | 59.8 | 69 | 0 | 69 | 82.6%(3-year) | |||
W.J. van Driel 2018 | Control Group | Primary | Netherlands | 63 | 122 | 0 | 122 | 38%(5-year) |
Experimental group | 61 | 118 | 0 | 118 | 50%(5-year) |
The association between HIPEC and OS
Studies (N) | HR (95%CI) |
I
2
| P value | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OS | PFS | OS without CC3 | PFS without CC3 | OS | PFS | OS withoutCC3 | PFS withoutCC3 | OS | PFS | OS withoutCC3 | PFS withoutCC3 | ||
HIPEC group vs non-HIPEC group | 13 | 0.54 (0.45-0.66) | 0.45(0.32-0.62) | 0.51(0.42-0.63) | 0.41(0.32-0.52) | 48% | 60% | 39% | 10% | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
Subgroup | |||||||||||||
Primary ovarian cancer | 6 | 0.59(0.46-0.75) | 0.41(0.32-0.54) | _ | _ | 34% | 32% | _ | _ | <0.0001 | <0.0001 | _ | _ |
Recurrent ovarian cancer | 5 | 0.45(0.24 to 0.83) | 0.55(0.27 to 1.11) | 0.38(0.25 to 0.56) | 0.41(0.27 to 0.62) | 60% | 77% | 0 | 0 | 0.01 | 0.09 | <0.0001 | <0.0001 |
Stage III-IV | 5 | 0.64(0.50 to 0.82) | 0.36(0.20 to 0.65) | _ | _ | 0 | 66% | - | - | 0.0004 | 0.0007 | - | - |
Interval CRS plus HIPEC | 2 | 0.61(0.45 to 0.83) | 0.29(0.1 to 0.86) | - | - | 50% | 80% | - | - | 0.002 | 0.03 | - | - |
Primary CRS plus HIPEC | 10 | 0.47(0.37 to 0.61) | 0.52(0.41 to 0.65) | 0.43(0.33 to 0.55) | 0.43(0.33 to 0.55) | 50% | 50% | 28% | 0 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |